natgillin/translations-raw huggingface dataset:
The following headings are used to rank the ADRs by frequency: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
The following list of adverse reactions is based on experience from clinical trials and on post- marketing experience and are displayed by system organ class and frequency of occurrence: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to
Sljedeći prikaz nuspojava temelji se na podacima iz kliničkih ispitivanja i postmarketinškog iskustva, a nuspojave su prikazane prema organskom sustavu i učestalosti pojavljivanja kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 1 below: very common ( 1/10); common ( 1/100 to &lt; 1/10); uncommon ( 1/1,000 to &lt; 1/100); rare ( 1/10,000 to &lt; 1/1,000); and not known (cannot be estimated from the available data).
Sljedeći popis nuspojava temelji se na iskustvu iz kliničkih ispitivanja i nakon stavljanja lijeka u promet, a prikazane su dolje u Tablici 1 prema organskom sustavu i učestalosti: vrlo često (≥ 1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 1 below: very common ( 1/10); common ( 1/100 to &lt; 1/10); uncommon ( 1/1000 to &lt; 1/100); rare ( 1/10,000 to &lt; 1/1,000); and not known (cannot be estimated from the available data).
Sljedeći popis nuspojava temelji se na iskustvu iz kliničkih ispitivanja i nakon stavljanja lijeka u promet, a prikazane su dolje u Tablici 1 prema organskom sustavu i učestalosti: vrlo često (≥ 1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 3 below: very common ( 1/10); common ( 1/100 to &lt; 1/10); uncommon ( 1/1,000 to &lt; 1/100); rare ( 1/10,000 to &lt; 1/1,000); and not known (cannot be estimated from the available data).
Sljedeći popis nuspojava temelji se na iskustvu iz kliničkih ispitivanja i nakon stavljanja lijeka u promet, a prikazane su dolje u Tablici 3 prema organskom sustavu i učestalosti: vrlo često (≥ 1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 3 below: very common ( 1/10); common ( 1/100 to &lt; 1/10); uncommon ( 1/1000 to &lt; 1/100); rare ( 1/10,000 to &lt; 1/1,000); and not known (cannot be estimated from the available data).
Sljedeći popis nuspojava temelji se na iskustvu iz kliničkih ispitivanja i nakon stavljanja lijeka u promet, a prikazane su dolje u Tablici 3 prema organskom sustavu i učestalosti: vrlo često (≥ 1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experienceand are displayed by system organ class and frequency in Table 3 below: very common ( 1/10); common ( 1/100 to &lt; 1/10); uncommon ( 1/1,000 to &lt; 1/100); rare ( 1/10,000 to &lt; 1/1,000); and not known (cannot be estimated from the available data).
Sljedeći popis nuspojava temelji se na iskustvu iz kliničkih ispitivanja i nakon stavljanja lijeka u promet, a prikazane su dolje u Tablici 3 prema organskom sustavu i učestalosti: vrlo često (≥ 1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following reactions have been reported with a frequency below 5% in the combination arm, but are included here for their clinical relevance: neutropenic infection ( &lt; 1%), neutropenic sepsis ( &lt; 1%), pancytopenia (1.8%), bone marrow failure (1.5%), granulocytopenia (1.5%), dehydration, insomnia, peripheral sensory neuropathy, syncope, left ventricular dysfunction ( &lt; 1%), pulmonary embolism (1.2%), pulmonary oedema ( &lt; 1%), cough, hepatotoxicity ( &lt; 1%), gamma-glutamyltransferase increased, bilirubin conjugated increased, musculoskeletal pain, myalgia, blood creatinine increased, oedema/peripheral oedema, catheter site reactions.
Sljedeće su reakcije prijavljene s učestalošću manjom od 5 % u skupini koja je primala kombinirano liječenje, ali su navedene ovdje zbog svoje kliničke važnosti: neutropenijska infekcija ( &lt; 1 %), neutropenijska sepsa ( &lt; 1 %), pancitopenija (1,8 %), zatajenje koštane srži (1,5 %), granulocitopenija (1,5 %), dehidracija, nesanica, periferna senzorna neuropatija, sinkopa, disfunkcija lijeve klijetke ( &lt; 1 %), plućna embolija (1,2 %), plućni edem ( &lt; 1 %), kašalj, hepatotoksičnost ( &lt; 1 %), povišena gama glutamiltransferaza, povišeni konjugirani bilirubin, bol u mišićno-koštanom sustavu, mialgija, povišeni kreatinin u krvi, edem/periferni edem, reakcije na mjestu katetera.
The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing incidence: very common (1/10); common (1/100 to &lt; 1/10); uncommon (1/1,000 to &lt; 1/100); rare (1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Sljedeće nuspojave povezane s primjenom lijeka zabilježene u kliničkim ispitivanjima prikazane su prema organskim sustavima i u padajućem nizu prema učestalosti : vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i  1/100); rijetko (≥ 1/10 000 i  1/1000); vrlo rijetko ( 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing incidence: very common (1/10); common (1/100 to &lt; 1/10); uncommon (1/1,000 to 1/100); rare (1/10,000 to 1/1,000); very rare (1/10,000), not known (cannot be estimated from the available data).
Sljedeće nuspojave povezane s primjenom lijeka zabilježene u kliničkim ispitivanjima prikazane su prema organskim sustavima i u padajućem nizu prema učestalosti : vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i  1/100); rijetko (≥ 1/10 000 i  1/1000); vrlo rijetko ( 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following related adverse reactions from clinical studies were listed below by system organ class and in order of decreasing incidence (very common: 1/10; common: 1/100 to &lt; 1/10; uncommon:
Sljedeće nuspojave povezane s primjenom lijeka zabilježene u kliničkim ispitivanjima prikazane su prema organskim sustavima i u padajućem nizu prema incidenciji (vrlo često: ≥ 1/10; često: ≥ 1/100 i
The following related adverse reactions from clinical trials are listed below as MedDRA preferred term by system organ class and in order of decreasing incidence (very common: ≥1/10; common:
Sljedeće nuspojave povezane s primjenom lijeka zabilježene u kliničkim ispitivanjima popisane su u nastavku kao MedDRA preferirani pojmovi prema organskim sustavima i u padajućem nizu prema učestalosti (vrlo često: ≥ 1/10; često: ≥ 1/100 i &lt; 1/10; manje često: ≥ 1/1000 i &lt; 1/100; rijetko:
The following table includes, the all-causality adverse reactions (MedDRA terms) from 840 subjects receiving 100 mg anidulafungin with frequency corresponding to very common (≥1/10), common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and from spontaneous reports with frequency not known (cannot be estimated from the available data).
Sljedeća tablica prikazuje nuspojave svih uzročnosti (MedDRA pojmovi) u 840 ispitanika koji su primali 100 mg anidulafungina, sa sljedećom učestalosti: vrlo često (1/10), često (1/100 i &lt; 1/10), manje često (1/1000 i &lt; 1/100), rijetko (1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) te iz spontanih prijava s nepoznatom učestalosti (ne može se procijeniti iz dostupnih podataka).
The following table of undesirable effects (first year of treatment) is based on adverse events that occurred at a frequency of &gt; 2 % and with an incidence  1 % above placebo in clinical trials of 1 and 2 years duration:
Sljedeća tablica nuspojava (prva godina liječenja) prikazuje štetne događaje koji su se pojavili s učestalošću &gt; 2 % i s incidencijom  1 % u odnosu na placebo u kliničkim ispitivanjima u trajanju od 1 i 2 godine:
The following table shows the percentage of subjects initially seronegative for rotavirus (IgA antibody titres &lt; 20 U/ml) (by ELISA) with serum anti-rotavirus IgA antibody titers  20U/ml one to two months after the second dose of vaccine or placebo as observed in different studies.
U sljedećoj tablici prikazan je postotak osoba koje su inicijalno bile seronegativne na rotavirus (titar IgA protutijela &lt; 20 U/ml) (ELISA), a koji su jedan do dva mjeseca nakon druge doze cjepiva ili placeba imali titar IgA protutijela protiv rotavirusa u serumu 20 U/ml, što je zabilježeno u različitim studijama.
The following table shows the percentage of subjects initially seronegative for rotavirus (IgA antibody titres &lt; 20 U/ml) (by ELISA) with serum anti-rotavirus IgA antibody titers 20U/ml one to two months after the second dose of vaccine or placebo as observed in different studies with Rotarix lyophilised formulation.
U sljedećoj tablici prikazan je postotak osoba koje su inicijalno bile seronegativne na rotavirus (titar IgA protutijela &lt; 20 U/ml) (ELISA), a koji su jedan do dva mjeseca nakon druge doze cjepiva ili placeba imali titar IgA protutijela protiv rotavirusa u serumu 20 U/ml, što je zabilježeno u različitim studijama s liofiliziranim oblikom cjepiva Rotarix.
The following terms and frequencies are applied: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), and not known (cannot be estimated from the available data).
Za učestalost pojavljivanja korištena je sljedeća klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following terms and frequencies are applied: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1000), very rare ( &lt; 1/10,000), and not known (cannot be estimated from the available data).
Za učestalost pojavljivanja korištena je sljedeća klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1 000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1 000), vrlo rijetko ( &lt; 1/10 000), i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following terms and frequencies are applied: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1000), very rare ( &lt; 1/10,000), and not known (cannot be estimated from the available data).
Za učestalost pojavljivanja korištena je sljedeća klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following terms and frequencies are applied: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1000), very rare ( &lt; 1 /10,000) and not known (cannot be estimated from the available data).
Koriste se sljedeći pojmovi i učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The following terms are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Upotrijebljeni su sljedeći izrazi za svrstavanje nuspojava na lijek prema učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), ili vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following terms are used to rank the ADRs by frequency: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Za prikaz učestalosti nuspojava koristili su se sljedeći termini: vrlo često (≥ 1/10); često (≥ 1/100 do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
The frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100).
Učestalost se definira na sljedeći način: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100).
The frequencies are defined as follows: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100).
Učestalost se definira na sljedeći način: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100).
The frequencies are defined as follows: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100) and not known (frequency cannot be estimated from available data).
Učestalost nuspojava definirana je kao: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100) i nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
The frequencies are defined as follows: Very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Učestalost je definirana na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequencies of adverse reactions are classified as very common ( &gt; 1/10), common ( &gt; 1/100, &lt; 1/10), uncommon ( &gt; 1/1,000, &lt; 1/100), rare ( &gt; 1/10,000, &lt; 1/1,000), and very rare ( &lt; 1/10,000).
Učestalosti nuspojava kategorizirane su kao vrlo često ( &gt; 1/10), često ( &gt; 1/100, &lt; 1/10), manje često ( &gt; 1/1000, &lt; 1/100), rijetko ( &gt; 1/10 000, &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
The frequencies of adverse reactions are ranked according to the following: Very common ( ≥ 1/10), Common (≥ 1/100 to &lt; 1/10), Uncommon (≥ 1/1,000 to &lt; 1/100), Rare (≥ 1/10,000 to &lt; 1/1,000), Very rare ( &lt; 1/10,000).
Učestalosti nuspojava navedene su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
The frequencies of adverse reactions are ranked according to the following: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Učestalosti nuspojava definirane su na sljedeći način: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequencies of adverse reactions are ranked according to the following: Very common (≥1/10), Common (≥1/100 to &lt; 1/10), Uncommon (≥1/1,000 to &lt; 1/100); rare ( &gt; 1/10,000, &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Učestalosti nuspojava izražene su kako slijedi: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100); rijetko ( &gt; 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequencies of the adverse reactions correspond with very common (1/10), common (1/100 to
Učestalost nuspojava može biti vrlo često (1/10), često (1/100 do &lt; 1/10), manje često (1/1000 do
The frequencies of the adverse reactions reported below are classified as very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10) and uncommon (≥ 1/1,000 to &lt; 1/100).
Učestalost navedenih nuspojava u nastavku određuje se kao vrlo česta (≥ 1/10), česta (≥ 1/100 i &lt; 1/10) i manje česta (≥ 1/1000 i &lt; 1/100).
The frequency categories are defined as follows: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100).
Kategorije po učestalosti definiraju se na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 do &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100).
The frequency categories are defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); and not known (cannot be estimated from the available data).
Kategorije učestalosti definirane su prema sljedećoj konvenciji: vrlo često (≥ 1/10); često (≥ 1/100 do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency is defined as follows: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from available data).
Učestalost je definirana na sljedeći način: vrlo često ( 1/10), često ( 1/100 i &lt; 1/10), manje često ( 1/1000 i &lt; 1/100), rijetko ( 1/10 000 i &lt; 1/1000), vrlo rijetko (≤ 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency listed below is defined using the following convention: common (≥ 1/100 to &lt; 1/10) and uncommon (≥ 1/1,000 to &lt; 1/100).
Učestalost nuspojava navedena u sljedećim tablicama definira se prema sljedećoj konvenciji: često (≥ 1/100 i &lt; 1/10) i manje često (≥ 1/1 000 i &lt; 1/100).
The frequency listed below is defined using the following convention: very common ( &gt; 1/10), common (≥ 1/100 to &lt; 1/10), not known (frequency cannot be estimated from available data).
Kategorije učestalosti navedene u nastavku definirane su na sljedeći način: vrlo često (≥1/10), često (≥ 1/100 i &lt; 1/10), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency of adverse events are classified as very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), and very rare ( &lt; 1/10,000).
Nuspojave se po učestalosti klasificiraju kao vrlo česte (≥1/10), česte (≥1/100 i &lt; 1/10), manje česte (≥1/1000 i &lt; 1/100), rijetke (≥1/10 000 i &lt; 1/1000) i vrlo rijetke ( &lt; 1/10 000).
The frequency of adverse reactions is classified as follows: Common: ≥ 1/100 to &lt; 1/10
Učestalost nuspojava klasificirana je na sljedeći način: Često: ≥ 1/100 i &lt; 1/10
The frequency of adverse reactions is defined as follows: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to
Učestalost nuspojava određuje se kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i
The frequency of adverse reactions is defined using the following convention: very common ( ≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000) and not known (cannot be estimated from available data).
Učestalost nuspojava definirana je kao: vrlo često ( ≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000) and not known (cannot be estimated from available data).
Učestalost nuspojava definirana je kao: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); and not known (cannot be estimated from available data).
Učestalost nuspojava definirana je na sljedeći način: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to
Učestalost niže navedenih nuspojava je definirana na sljedeći način: vrlo često (≥1/10), često (≥1/100 i
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to
Učestalost nuspojava definira se prema slijedećem prikazu učestalosti nuspojava: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10000 i
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Učestalost nuspojava u nastavku teksta definira se na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Učestalost nuspojava u nastavku teksta definira se na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 do &lt; 1/10); manje često (≥ 1/1.000 do &lt; 1/100); rijetko (≥ 1/10.000 do &lt; 1/1.000); vrlo rijetko ( &lt; 1/10.000).